Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
AUTOR(ES)
Bratt, O
FONTE
Nature Publishing Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2768463Documentos Relacionados
- Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer
- Castration-resistant prostate cancer: systemic therapy in 2012
- Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
- Increased expression of class III β-tubulin in castration-resistant human prostate cancer
- Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium